Kelly Steven 4
4 · Carisma Therapeutics Inc. · Filed Feb 2, 2024
Insider Transaction Report
Form 4
Kelly Steven
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2024-01-31+438,000→ 438,000 totalExercise: $2.10Exp: 2034-01-31→ Common Stock (438,000 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest over four years in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.